Telix Pharmaceuticals chief executive Christian Behrenbruch says the company could double sales in the next four years as its three new cancer treatment products hit the market and nuclear medicine emerges from the “spotty teenager phase”.
Telix CEO Christian Behrenbruch has reaffirmed full-year revenue guidance.
Loading...
Michael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
